Literature DB >> 28057953

Daclizumab.

Anne P Kim, Danial E Baker.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The December 2016 monograph topics are ozenoxacin cream, ocrelizumab, naldemedine, eteplirsen, and abaloparatide. The Safety MUE is on buprenorphine buccal.

Entities:  

Year:  2016        PMID： 28057953      PMCID： PMC5199226          DOI： 10.1310/hpj5111-928

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  35 in total

1.  Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

Authors:  Monica A Rojas; Noel G Carlson; Thomas L Miller; John W Rose
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

2.  Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis.

Authors:  Wenzheng Jiang; Noo Ri Chai; Dragan Maric; Bibiana Bielekova
Journal:  J Immunol       Date:  2011-06-10       Impact factor: 5.422

3.  Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.

Authors:  Lei Diao; Yaming Hang; Ahmed A Othman; Ivan Nestorov; Jonathan Q Tran
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

4.  Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.

Authors:  James P Sheridan; Ying Zhang; Katherine Riester; Meina T Tang; Lyubov Efros; Jia Shi; Jeffrey Harris; Vladimir Vexler; Jacob S Elkins
Journal:  Mult Scler       Date:  2011-08-01       Impact factor: 6.312

5.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Authors:  Ralf Gold; Gavin Giovannoni; Krzysztof Selmaj; Eva Havrdova; Xavier Montalban; Ernst-Wilhelm Radue; Dusan Stefoski; Randy Robinson; Katherine Riester; Jitesh Rana; Jacob Elkins; Gilmore O'Neill
Journal:  Lancet       Date:  2013-04-04       Impact factor: 79.321

6.  Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.

Authors:  Mukul Minocha; Jonathan Q Tran; James P Sheridan; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

7.  Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Ludwig Kappos; Heinz Wiendl; Krzysztof Selmaj; Douglas L Arnold; Eva Havrdova; Alexey Boyko; Michael Kaufman; John Rose; Steven Greenberg; Marianne Sweetser; Katherine Riester; Gilmore O'Neill; Jacob Elkins
Journal:  N Engl J Med       Date:  2015-10-08       Impact factor: 91.245

8.  Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.

Authors:  Y Zhang; M McClellan; L Efros; D Shi; B Bielekova; M T Tang; V Vexler; J P Sheridan
Journal:  Mult Scler       Date:  2013-07-11       Impact factor: 6.312

9.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Gregg Blevins; Silva Markovic-Plese; Jennifer McCartin; Joseph A Frank; Jens Würfel; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

10.  Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.

Authors:  Jonathan Q Tran; Ahmed A Othman; Alvydas Mikulskis; Paul Wolstencroft; Jacob Elkins
Journal:  Clin Pharmacol       Date:  2016-02-11
View more
  3 in total

Review 1.  Hybridoma technology: is it still useful?

Authors:  Jane Zveiter Moraes; Bárbara Hamaguchi; Camila Braggion; Enzo Reina Speciale; Fernanda Beatriz Viana Cesar; Gabriela de Fátima da Silva Soares; Juliana Harumi Osaki; Tauane Mathias Pereira; Rodrigo Barbosa Aguiar
Journal:  Curr Res Immunol       Date:  2021-03-22

Review 2.  Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.

Authors:  Stelios Kasikis; Aaron Etra; John E Levine
Journal:  BioDrugs       Date:  2021-01       Impact factor: 5.807

3.  A computational approach based on the colored Petri net formalism for studying multiple sclerosis.

Authors:  Simone Pernice; Marzio Pennisi; Greta Romano; Alessandro Maglione; Santina Cutrupi; Francesco Pappalardo; Gianfranco Balbo; Marco Beccuti; Francesca Cordero; Raffaele A Calogero
Journal:  BMC Bioinformatics       Date:  2019-12-10       Impact factor: 3.169
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.